Industry News

Published on May 2016
On May 8, International Thalassaemia Day, ApoPharma Inc. thinks of the people whose lives are impacted by this condition, and recommits to working on their behalf.  As they salute their courage, strength, and accomplishments, they also remember their needs and concerns, and seek to give our best effort in all...
read more
Published on May 2016
  Resonance Health is delighted to announce that Chief Scientific Officer Professor Tim St Pierre has received a significant award from the Thalassemia International Federation (TIF), in recognition of the contribution made by FerriScan, the MRI-based measurement for liver iron concentration (LIC), to the lives of patients worldwide. TIF is dedicated to...
read more
Published on May 2016
The ‪‎BELIEVE‬‪ ‎researchers‬ are studying an ‎investigational‬ ‎drug‬ called ‎luspatercept‬ to see if it may reduce the number of transfusions you require! If you are 18 years of age or older and have β-thalassaemia requiring regular blood transfusions, you may be eligible to take part in the BELIEVE Study. Your doctor is the best source of information about your condition and its...
read more
Published on Mar 2016
Trial of ‪‎Merganser‬'s beta ‪‎thalassemia‬ ‪‎drug‬ candidate begins a ‪‎clinical‬ ‪‎trial‬ is underway to evaluate Merganser Biotech's M012, which is being developed as a treatment candidate for conditions such as beta thalassemia and some subtypes of myelodysplasia....
read more
Published on Feb 2016
The Novartis Declaration for Patients - What Patients Can Expect Introduction We are inspired by patients. This inspiration motivates us to revolutionize the research, development and manufacturing of innovative, high-quality medicines that help people live longer, with a better quality of life, giving more time to do the things that matter to them. To...
read more
Published on May 2015
Bluebird‬ bio, Inc. announced that it has met with regulatory authorities in EU and USA to discuss potential ‪‎approval‬ pathways for its ‪‎LentiGlobin‬ BB305 for the treatment of beta-‪‎thalassemia‬ major. These discussions have resulted in general agreement from both agencies regarding bluebird bio's development plans, which could potentially result in accelerated...
read more
Published on May 2015
Update on Luspatercept (ACE-536) Phase 2 Study for the Treatment of Adults with Transfusion Dependent and Non-Transfusion Dependent Beta-Thalassemia We are delighted to share with you a webcast with Dr Antonio Piga presenting the most recent Luspatercept Phase 2 data (ASH 2014 conference). This will serve nicely as a primer for...
read more
Published on Jan 2015
It is that time again, time for the 11th annual Iron Warriors® Art Contest! Here’s your chance to show off your creativity! The purpose of the contest is to raise awareness about Thalassaemia and the importance of treatment compliance for everyone, and to give you a chance to show off your...
read more
Published on Dec 2014
New clinical data from bluebird bio gene therapy studies was released at the annual meeting of the American Society of Hematology in San Francisco  We would like alert you to some new clinical data from bluebird bio gene therapy studies that was released at the annual meeting of the American Society...
read more
Published on Dec 2014
We would like to share an important update regarding the preliminary results from a Phase 2 Study presented during the 56th American Society of Hematology (ASH) Annual Meeting & Exposition on 7 December 2014 in San Francisco. The recent data have shown that Luspatercept (ACE-536) has increased Hemoglobin and decreased...
read more
Published on Nov 2014
It is that time again, time for the 10th annual Iron Warriors® Art Contest! The purpose of the contest is to raise awareness about Thalassaemia, the importance of treatment compliance for all patients, and to give patients a chance to show off their artwork. Children with Thalassaemia in your region are invited...
read more
Published on Nov 2013
TIF welcomes the creation of lay material in an effort to spread awareness, knowledge and education. Please view the video below launched by Novartis and the Iron Health Alliance mixing animation with medical expert opinion to provide a unique overview about NTDT To view the infographic explaining how iron works in the body, click here To view the...
read more